Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?
cancer syndromes
gene panel
genetic testing
multilocus inherited neoplasia alleles syndrome
Journal
Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
03
09
2018
revised:
24
10
2018
accepted:
28
10
2018
pubmed:
24
12
2018
medline:
4
6
2020
entrez:
24
12
2018
Statut:
ppublish
Résumé
Genetic testing of hereditary cancer using comprehensive gene panels can identify patients with more than one pathogenic mutation in high and/or moderate-risk-associated cancer genes. This phenomenon is known as multilocus inherited neoplasia alleles syndrome (MINAS), which has been potentially linked to more severe clinical manifestations. To determine the prevalence and clinical features of MINAS in a large cohort of adult patients with hereditary cancer homogeneously tested with the same gene panel. A cohort of 1023 unrelated patients with suspicion of hereditary cancer was screened using a validated panel including up to 135 genes associated with hereditary cancer and phakomatoses. Thirteen (1.37%) patients harbouring two pathogenic mutations in dominant cancer-predisposing genes were identified, representing 5.7% (13/226) of patients with pathogenic mutations. Most (10/13) of these cases presented clinical manifestations associated with only one of the mutations identified. One case showed mutations in Genetic analysis of a broad cancer gene panel identified the largest series of patients with MINAS described in a single study. Overall, our data do not support the existence of more severe manifestations in double mutants at the time of diagnosis although they do confirm previous evidence of severe phenotype in biallelic
Identifiants
pubmed: 30580288
pii: jmedgenet-2018-105700
doi: 10.1136/jmedgenet-2018-105700
pmc: PMC6678040
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-525Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Med Genet. 2014 Jun;51(6):355-65
pubmed: 24737826
Breast Cancer Res. 2016 Nov 11;18(1):112
pubmed: 27836010
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
J Clin Oncol. 2016 Dec;34(34):4071-4078
pubmed: 27621404
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Am J Hum Genet. 2018 Jul 5;103(1):3-18
pubmed: 29909963
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Fam Cancer. 2018 Jan;17(1):87-90
pubmed: 28600700
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Cancer. 2015 Jan 1;121(1):25-33
pubmed: 25186627
Hum Genet. 2013 Oct;132(10):1077-130
pubmed: 23820649
J Clin Oncol. 2016 May 1;34(13):1455-9
pubmed: 26786923
JAMA Oncol. 2016 Mar;2(3):373-9
pubmed: 26659639
Sci Rep. 2017 Jan 04;7:39348
pubmed: 28051113
Nat Rev Cancer. 2004 Sep;4(9):665-76
pubmed: 15343273
J Med Genet. 2011 Dec;48(12):860-3
pubmed: 22058428